Biosimilar Medicines

Department of Health and Social Care written question – answered on 14th February 2019.

Alert me about debates like this

Photo of Chris Green Chris Green Conservative, Bolton West

To ask the Secretary of State for Health and Social Care, what steps NHS Improvement is taking to ensure that hospital trusts across the NHS are following shared decision-making principles and patient consent guidance within NHS England's Commissioning framework for biological medicines (including biosimilar medicines) when implementing biosimilar switching programmes.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary for Health and Social Care

NHS Improvement does not monitor use of shared decision making. It instead monitors uptake of the biosimilars as against the original – usually patented – medicines.

It does, however, hold a joint role in supporting the National Health Service to use the best value biologic medicine which is part of a long standing programme of work connected to the NHS Biosimilar Medicines Programme Board, the NHS England Medicines Value Programme and the NHS Improvement Top 10 Medicines remit.

The biosimilars medicines programme board is intended to ensure appropriate use of biosimilar medicines across the NHS in England. This includes shared decision making and patient consent and the board has produced guidance which sets out the importance of shared decision making which is fully endorsed by patient groups.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.